Pharsight

Albireo patents expiration

1. Bylvay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7132416 ALBIREO Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia
Sep, 2022

(1 year, 5 months ago)

US10975046 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10093697 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10487111 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10981952 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US9694018 ALBIREO IBAT inhibitors for the treatment of liver disease
Nov, 2031

(7 years from now)

US10011633 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US11732006 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US11365182 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(15 years from now)

US11802115 ALBIREO Pharmaceutical formulation of odevixibat
Jun, 2039

(15 years from now)

US11801226 ALBIREO Pharmaceutical formulation of odevixibat
Jun, 2039

(15 years from now)

US11583539 ALBIREO Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
Nov, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028
New Indication (I) Jun 13, 2026

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of reducing serum bile acids in patients 3 months or older sufferi...

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

BYLVAY family patents

Family Patents